VR Gaming Therapy for Stroke Rehabilitation

N/A

Waitlist Available

Led By Seema S Aggarwal, PhD, APRN, AGNP-C

Research Sponsored by The University of Texas Health Science Center, Houston

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, after each session (3 times a week for 4 weeks about 12 total sessions)

Awards & highlights

No Placebo-Only Group

Summary

This trial tests if a virtual reality game can help stroke survivors with arm and cognitive impairments, and the impact it has on caregivers.

Who is the study for?

This trial is for chronic stroke survivors who had a stroke between 6 months to 2 years ago, can communicate in English, and are able to consent. They should have mild-moderate cognitive and arm impairments but cannot join if they have severe cognitive issues, certain neurological deficits like aphasia or hemiopsia, motion sickness/vertigo/dizziness/seizures, claustrophobia, blindness/deafness or can't hold the controller.

What is being tested?

The study tests how feasible and acceptable it is for stroke survivors with arm and cognitive impairments to use Oculus VR technology for rehabilitation. It measures changes in their abilities using standard tests and includes interviews with caregivers about their involvement in the rehab process.

What are the potential side effects?

Potential side effects of using Oculus VR may include discomfort such as dizziness or nausea (especially if prone to motion sickness), eye strain from prolonged screen exposure, headaches due to virtual reality immersion or fatigue from physical activity during gaming.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, after each session (3 times a week for 4 weeks about 12 total sessions)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, after each session (3 times a week for 4 weeks about 12 total sessions)

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, after each session (3 times a week for 4 weeks about 12 total sessions) for reporting.